8-K
filed February 21, 2023, 6:59 PM ET
ticker PTCT
CIK 0001070081
earnings
confidence high
sentiment positive
materiality 0.70
PTC Therapeutics reports 2022 revenue of $699M (+30% YoY); reaffirms 2023 guidance of $940M-$1B
PTC THERAPEUTICS, INC.
2022-FY EPS reported
-$7.79
revenue$698,801,000
- 2022 total revenue $698.8M (+30% YoY); DMD franchise $507M (+20% YoY).
- Translarna net revenue $288.6M; Emflaza $218.3M; Evrysdi royalty $113.5M.
- Net loss $559M for 2022; cash $410.7M at Dec 31, 2022.
- 2023 guidance: total revenue $940M-$1B; DMD franchise $545M-$565M.
- Four key study readouts expected H1 2023: sepiapterin PKU (May), vatiquinone MIT-E and MOVE-FA, PTC518 HD (Q2).
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
PTC THERAPEUTICS, INC. reported the fourth quarter ended December 31, 2022 results: revenue $167.4 million. Guidance reaffirmed.
- Period
- the fourth quarter ended December 31, 2022
- Revenue
- $167.4 million
- Guidance
- reaffirmed
- Result
- reported results
Exact text from the filing
Total revenues were $167.4 million for the fourth quarter of 2022
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
PTC THERAPEUTICS, INC. reported the fiscal year ended December 31, 2022 results: revenue $698.8 million. Guidance reaffirmed.
- Period
- the fiscal year ended December 31, 2022
- Revenue
- $698.8 million
- Guidance
- reaffirmed
- Result
- reported results
Exact text from the filing
Total revenues were $698.8 million for the full year 2022
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.